What is STANDARD BIOTOOLS INC's earnings per share (EPS)?

STANDARD BIOTOOLS INC (LAB) reported diluted earnings per share of $-0.20 for fiscal year 2025. This represents a 61.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

STANDARD BIOTOOLS INC Financials

LAB

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows STANDARD BIOTOOLS INC (LAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LAB FY2025 2026-05-06

A cash-rich balance sheet is funding a subscale business whose 49.9% gross margin still cannot cover overhead.

Even after two years of gross-margin improvement, FY2025 still produced 49.9% gross margin alongside operating cash burn of -$74.3M, showing the constraint is the expense base rather than the product economics. The smaller FY2025 net loss therefore overstates progress, because the core business still posted a large operating loss of -$110.2M.

FY2025 showed ample liquidity and a much cleaner balance sheet, with cash of $120.9M against total liabilities of $143.5M. That is a very different posture from the negative-equity setup in FY2022-FY2023, so the immediate pressure is not refinancing but whether recurring burn shrinks before the cash cushion does.

The operating model remains overhead-heavy: FY2025 gross profit of $42.5M sat far below SG&A of $109.9M, even before R&D spending. That gap means modest revenue moves do not change the outcome much; gross-margin gains will matter only if the company carries a much leaner cost structure or a much larger sales base.

Financial Health Signals

Financial Health Score 39/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of STANDARD BIOTOOLS INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-1.33

STANDARD BIOTOOLS INC scores -1.33, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($367.1M) relative to total liabilities ($143.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

STANDARD BIOTOOLS INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, STANDARD BIOTOOLS INC generates $0.99 in operating cash flow (-$74.3M OCF vs -$74.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4240.3x

STANDARD BIOTOOLS INC earns $-4240.3 in operating income for every $1 of interest expense (-$110.2M vs $26K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$85.3M

YoY-6.2%

5Y CAGR-9.2%

10Y CAGR-2.9%

STANDARD BIOTOOLS INC generated $85.3M in revenue in fiscal year 2025. This represents a decrease of 6.2% from the prior year.

EBITDA

-$101.0M

YoY+12.3%

STANDARD BIOTOOLS INC's EBITDA was -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.3% from the prior year.

Net Income

-$74.9M

YoY+46.1%

STANDARD BIOTOOLS INC reported -$74.9M in net income in fiscal year 2025. This represents an increase of 46.1% from the prior year.

EPS (Diluted)

$-0.20

YoY+61.5%

STANDARD BIOTOOLS INC earned $-0.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$82.6M

YoY+45.6%

STANDARD BIOTOOLS INC generated -$82.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.6% from the prior year.

Cash & Debt

$120.9M

YoY-27.5%

5Y CAGR+12.0%

10Y CAGR+15.3%

STANDARD BIOTOOLS INC held $120.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

386M

YoY+2.3%

STANDARD BIOTOOLS INC had 386M shares outstanding in fiscal year 2025. This represents an increase of 2.3% from the prior year.

Margins & Returns

Gross Margin

49.9%

YoY+0.5pp

10Y CAGR-49.9pp

STANDARD BIOTOOLS INC's gross margin was 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

-129.2%

YoY+10.9pp

5Y CAGR-92.3pp

10Y CAGR-85.5pp

STANDARD BIOTOOLS INC's operating margin was -129.2% in fiscal year 2025, reflecting core business profitability. This is up 10.9 percentage points from the prior year.

Net Margin

-87.8%

YoY+64.8pp

5Y CAGR-49.4pp

10Y CAGR-41.3pp

STANDARD BIOTOOLS INC's net profit margin was -87.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 64.8 percentage points from the prior year.

Return on Equity

-17.6%

YoY+11.8pp

5Y CAGR+20.5pp

10Y CAGR+28.8pp

STANDARD BIOTOOLS INC's ROE was -17.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 11.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.0M

YoY-9.9%

5Y CAGR-6.5%

10Y CAGR-4.0%

STANDARD BIOTOOLS INC invested $26.0M in research and development in fiscal year 2025. This represents a decrease of 9.9% from the prior year.

Share Buybacks

YoY-100.0%

STANDARD BIOTOOLS INC spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

$8.3M

YoY-0.6%

5Y CAGR-8.2%

10Y CAGR+7.6%

STANDARD BIOTOOLS INC invested $8.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.6% from the prior year.

LAB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$85.3M-6.2%	$91.0M-14.4%	$106.3M+8.6%	$97.9M-25.0%	$130.6M-5.5%	$138.1M
Cost of Revenue	$42.8M-7.2%	$46.1M-17.5%	$55.9M-8.2%	$60.9M	N/A	N/A
Gross Profit	$42.5M-5.2%	$44.9M-11.0%	$50.5M+36.2%	$37.1M	N/A	N/A
R&D Expenses	$26.0M-9.9%	$28.8M+11.1%	$25.9M-30.6%	$37.4M-1.5%	$37.9M+4.1%	$36.5M
SG&A Expenses	$109.9M+6.6%	$103.1M+17.7%	$87.5M-14.4%	$102.3M+3.4%	$98.9M+1.0%	$97.9M
Operating Income	-$110.2M+13.5%	-$127.5M-66.4%	-$76.6M+34.1%	-$116.2M-72.3%	-$67.5M-32.2%	-$51.0M
Interest Expense	$26K-99.2%	$3.3M-27.4%	$4.6M+5.4%	$4.3M+13.3%	$3.8M+7.0%	$3.6M
Income Tax	-$37.9M-7088.2%	$542K+19.9%	$452K+116.0%	-$2.8M+36.0%	-$4.4M-309.2%	-$1.1M
Net Income	-$74.9M+46.1%	-$138.9M-86.0%	-$74.7M+60.7%	-$190.1M-220.9%	-$59.2M-11.7%	-$53.0M
EPS (Diluted)	$-0.20+61.5%	$-0.52	$-0.94+61.3%	$-2.43-211.5%	$-0.78-5.4%	$-0.74

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$21.1M-11.1%	$23.8M+21.7%	$19.6M-10.2%	$21.8M+7.6%	$20.2M+2172.1%	$890K-96.0%	$22.1M-1.8%	$22.5M
Cost of Revenue	$9.8M-20.7%	$12.4M+23.3%	$10.1M-9.6%	$11.1M+21.4%	$9.2M+240.4%	$2.7M-72.9%	$10.0M-17.8%	$12.1M
Gross Profit	$11.3M-0.7%	$11.4M+20.0%	$9.5M-10.8%	$10.6M-3.8%	$11.0M+712.1%	-$1.8M-114.9%	$12.1M+16.9%	$10.4M
R&D Expenses	$2.1M-73.4%	$8.0M+25.4%	$6.4M+2.2%	$6.2M+14.4%	$5.4M+508.4%	-$1.3M-119.2%	$6.9M-4.2%	$7.2M
SG&A Expenses	$18.6M-26.6%	$25.3M-4.7%	$26.6M-5.4%	$28.1M-5.8%	$29.8M+339.3%	$6.8M-72.3%	$24.5M-1.6%	$24.9M
Operating Income	-$12.5M+49.3%	-$24.6M+25.2%	-$32.9M-28.2%	-$25.7M+4.7%	-$27.0M-160.8%	-$10.3M+61.3%	-$26.7M+11.8%	-$30.3M
Interest Expense	N/A	$5K-50.0%	$10K+11.1%	$9K+350.0%	$2K-99.7%	$572K-32.9%	$853K-0.6%	$858K
Income Tax	$11K+100.0%	-$35.9M-2854.9%	-$1.2M-99.7%	-$609K-411.8%	-$119K-146.3%	$257K+117.8%	$118K+202.6%	$39K
Net Income	$127.1M+559.0%	$19.3M+155.6%	-$34.7M-3.7%	-$33.5M-28.5%	-$26.0M+23.6%	-$34.1M-26.5%	-$26.9M+41.1%	-$45.7M
EPS (Diluted)	$0.33	N/A	$-0.090.0%	$-0.09-28.6%	$-0.07	N/A	$-0.07+41.7%	$-0.12

LAB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$567.8M-7.3%	$612.3M+89.5%	$323.1M-17.2%	$390.3M+41.8%	$275.2M-15.3%	$324.8M
Current Assets	$454.3M+20.9%	$375.9M+137.6%	$158.2M-24.2%	$208.8M+189.8%	$72.1M-38.8%	$117.7M
Cash & Equivalents	$120.9M-27.5%	$166.7M+222.5%	$51.7M-36.4%	$81.3M+185.8%	$28.5M-58.5%	$68.5M
Inventory	$20.0M-3.7%	$20.7M+1.0%	$20.5M-4.4%	$21.5M+3.1%	$20.8M+5.8%	$19.7M
Accounts Receivable	$13.4M-8.9%	$14.7M-25.0%	$19.7M+13.8%	$17.3M-5.7%	$18.3M-27.9%	$25.4M
Goodwill	N/A	$111.3M+4.7%	$106.3M+0.1%	$106.3M-0.1%	$106.4M-0.2%	$106.6M
Total Liabilities	$143.5M+2.0%	$140.6M-70.2%	$471.1M-0.1%	$471.8M+161.2%	$180.6M-2.7%	$185.7M
Current Liabilities	$108.3M+64.4%	$65.9M-39.7%	$109.3M+151.7%	$43.4M-12.4%	$49.6M-8.6%	$54.2M
Long-Term Debt	N/A	$299K-99.5%	$63.5M-2.1%	$64.9M	N/A	N/A
Total Equity	$424.3M-10.1%	$471.7M+418.6%	-$148.1M-81.7%	-$81.5M-186.1%	$94.6M-32.0%	$139.1M
Retained Earnings	-$1.3B-6.3%	-$1.2B-18.5%	-$1.0B-8.1%	-$926.1M-25.8%	-$736.0M-8.8%	-$676.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$639.1M+12.6%	$567.8M+5.2%	$539.6M-3.1%	$557.0M-3.9%	$579.6M-5.3%	$612.3M-10.2%	$681.5M-3.8%	$708.7M
Current Assets	$521.5M+14.8%	$454.3M-3.8%	$472.4M-6.6%	$506.0M+47.1%	$344.0M-8.5%	$375.9M-17.1%	$453.6M-5.5%	$480.0M
Cash & Equivalents	$265.8M+119.9%	$120.9M-6.6%	$129.4M-18.4%	$158.6M+5.1%	$150.9M-9.5%	$166.7M-20.8%	$210.6M-21.9%	$269.8M
Inventory	$18.6M-6.9%	$20.0M-21.4%	$25.4M+5.2%	$24.2M-42.6%	$42.1M+103.1%	$20.7M-51.4%	$42.6M+0.1%	$42.6M
Accounts Receivable	$16.6M+23.9%	$13.4M-0.8%	$13.5M-7.4%	$14.6M-58.8%	$35.5M+140.7%	$14.7M-58.3%	$35.3M+8.9%	$32.4M
Goodwill	N/A	N/A	N/A	N/A	$111.7M+0.4%	$111.3M+4.7%	$106.3M+0.1%	$106.3M
Total Liabilities	$78.0M-45.6%	$143.5M+2.5%	$140.0M+5.7%	$132.4M+5.9%	$125.0M-11.1%	$140.6M-26.8%	$192.2M-3.2%	$198.5M
Current Liabilities	$42.2M-61.0%	$108.3M+0.3%	$108.0M+10.1%	$98.0M+74.3%	$56.2M-14.7%	$65.9M-45.4%	$120.6M-2.6%	$123.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$299K-99.5%	$55.2M+0.2%	$55.1M
Total Equity	$561.1M+32.2%	$424.3M+6.2%	$399.7M-5.9%	$424.5M-6.6%	$454.6M-3.6%	$471.7M-3.6%	$489.3M-4.1%	$510.3M
Retained Earnings	-$1.1B+10.1%	-$1.3B+1.5%	-$1.3B-2.8%	-$1.2B-2.8%	-$1.2B-2.2%	-$1.2B-3.0%	-$1.2B-2.4%	-$1.1B

LAB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$74.3M+48.2%	-$143.5M-231.4%	-$43.3M+51.6%	-$89.4M-102.8%	-$44.1M-185.8%	-$15.4M
Capital Expenditures	$8.3M-0.6%	$8.4M+195.1%	$2.8M-26.0%	$3.8M-71.2%	$13.3M+4.3%	$12.7M
Free Cash Flow	-$82.6M+45.6%	-$151.8M-229.2%	-$46.1M+50.5%	-$93.2M-62.6%	-$57.3M-103.8%	-$28.1M
Investing Cash Flow	$27.4M-92.5%	$363.2M+1694.6%	$20.2M+123.0%	-$88.1M-637.7%	-$11.9M-129.9%	$40.0M
Financing Cash Flow	$570K+100.6%	-$102.6M-1407.1%	-$6.8M-103.0%	$230.8M+1345.9%	$16.0M-23.5%	$20.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$40.5M+647.9%	$5.4M+861.6%	$563K	$0	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$46.6M-3815.7%	-$1.2M+94.6%	-$22.2M-7.4%	-$20.7M+31.8%	-$30.3M-115.4%	-$14.1M+49.6%	-$27.9M+28.6%	-$39.0M
Capital Expenditures	$570K+19.7%	$476K-46.3%	$886K-53.0%	$1.9M-62.7%	$5.1M+49.4%	$3.4M+50.0%	$2.3M+16.4%	$1.9M
Free Cash Flow	-$47.2M-2731.2%	-$1.7M+92.8%	-$23.1M-2.4%	-$22.6M+36.2%	-$35.3M-102.6%	-$17.4M+42.1%	-$30.1M+26.5%	-$41.0M
Investing Cash Flow	$191.1M+2476.7%	-$8.0M-20.3%	-$6.7M-124.3%	$27.5M+88.1%	$14.6M-43.2%	$25.7M+183.3%	-$30.9M-161.5%	$50.3M
Financing Cash Flow	-$40K-106.5%	$620K+653.6%	-$112K-203.7%	$108K+334.8%	-$46K+99.9%	-$54.5M-2725900.0%	-$2K+100.0%	-$28.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0	$0	$0	$0	$0	$0-100.0%	$29.4M

LAB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	49.9%+0.5pp	49.3%+1.9pp	47.4%+9.6pp	37.8%	N/A	N/A
Operating Margin	-129.2%+10.9pp	-140.1%-68.0pp	-72.0%+46.6pp	-118.6%-67.0pp	-51.7%-14.7pp	-36.9%
Net Margin	-87.8%+64.8pp	-152.6%-82.4pp	-70.2%+123.9pp	-194.1%-148.7pp	-45.4%-7.0pp	-38.4%
Return on Equity	-17.6%+11.8pp	-29.4%	N/A	N/A	-62.6%-24.5pp	-38.1%
Return on Assets	-13.2%+9.5pp	-22.7%+0.4pp	-23.1%+25.6pp	-48.7%-27.2pp	-21.5%-5.2pp	-16.3%
Current Ratio	4.19-1.5	5.70+4.3	1.45-3.4	4.81+3.4	1.45-0.7	2.17
Debt-to-Equity	0.34+0.3	0.00+0.4	-0.43+0.4	-0.80-2.7	1.91+0.6	1.34
FCF Margin	-96.9%+70.0pp	-166.8%-123.4pp	-43.4%+51.8pp	-95.2%-51.2pp	-43.9%-23.5pp	-20.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	53.5%+5.7pp	47.8%-0.7pp	48.5%-0.3pp	48.8%-5.8pp	54.6%+257.4pp	-202.8%-257.7pp	54.9%+8.8pp	46.1%
Operating Margin	-59.1%+44.5pp	-103.6%+64.9pp	-168.5%-50.4pp	-118.1%+15.3pp	-133.4%+1028.8pp	-1162.1%-1041.2pp	-120.9%+13.6pp	-134.5%
Net Margin	600.9%+519.9pp	81.0%+258.5pp	-177.4%-23.7pp	-153.8%-25.0pp	-128.7%+3699.6pp	-3828.3%-3706.3pp	-122.0%+81.3pp	-203.3%
Return on Equity	22.7%+18.1pp	4.5%+13.2pp	-8.7%-0.8pp	-7.9%-2.1pp	-5.7%+1.5pp	-7.2%-1.7pp	-5.5%+3.4pp	-9.0%
Return on Assets	19.9%+16.5pp	3.4%+9.8pp	-6.4%-0.4pp	-6.0%-1.5pp	-4.5%+1.1pp	-5.6%-1.6pp	-4.0%+2.5pp	-6.5%
Current Ratio	12.36+8.2	4.19-0.2	4.38-0.8	5.16-1.0	6.12+0.4	5.70+1.9	3.76-0.1	3.88
Debt-to-Equity	0.14-0.2	0.34-0.0	0.35+0.0	0.31+0.0	0.28+0.3	0.00-0.1	0.110.0	0.11
FCF Margin	-223.1%-216.1pp	-7.0%+111.1pp	-118.1%-14.5pp	-103.6%+71.1pp	-174.8%+1784.9pp	-1959.7%-1823.3pp	-136.4%+45.8pp	-182.2%

Similar Companies

ZIMVIE INC ZIMV

$535.7M

Cytek Biosciences, Inc. CTKB

$592.8M

Bioventus Inc. BVS

$827.9M

Orthopedia KIDS

$519.6M

Avanos Medical AVNS

$1.2B

Frequently Asked Questions

What is STANDARD BIOTOOLS INC's annual revenue?

STANDARD BIOTOOLS INC (LAB) reported $85.3M in total revenue for fiscal year 2025. This represents a -6.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is STANDARD BIOTOOLS INC's revenue growing?

STANDARD BIOTOOLS INC (LAB) revenue declined by 6.2% year-over-year, from $91.0M to $85.3M in fiscal year 2025.

Is STANDARD BIOTOOLS INC profitable?

No, STANDARD BIOTOOLS INC (LAB) reported a net income of -$74.9M in fiscal year 2025, with a net profit margin of -87.8%.

What is STANDARD BIOTOOLS INC's EBITDA?

STANDARD BIOTOOLS INC (LAB) had EBITDA of -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is STANDARD BIOTOOLS INC's gross margin?

STANDARD BIOTOOLS INC (LAB) had a gross margin of 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is STANDARD BIOTOOLS INC's operating margin?

STANDARD BIOTOOLS INC (LAB) had an operating margin of -129.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is STANDARD BIOTOOLS INC's net profit margin?

STANDARD BIOTOOLS INC (LAB) had a net profit margin of -87.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is STANDARD BIOTOOLS INC's return on equity (ROE)?

STANDARD BIOTOOLS INC (LAB) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is STANDARD BIOTOOLS INC's free cash flow?

STANDARD BIOTOOLS INC (LAB) generated -$82.6M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is STANDARD BIOTOOLS INC's operating cash flow?

STANDARD BIOTOOLS INC (LAB) generated -$74.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are STANDARD BIOTOOLS INC's total assets?

STANDARD BIOTOOLS INC (LAB) had $567.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are STANDARD BIOTOOLS INC's capital expenditures?

STANDARD BIOTOOLS INC (LAB) invested $8.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does STANDARD BIOTOOLS INC spend on research and development?

STANDARD BIOTOOLS INC (LAB) invested $26.0M in research and development during fiscal year 2025.

How many shares does STANDARD BIOTOOLS INC have outstanding?

STANDARD BIOTOOLS INC (LAB) had 386M shares outstanding as of fiscal year 2025.

What is STANDARD BIOTOOLS INC's current ratio?

STANDARD BIOTOOLS INC (LAB) had a current ratio of 4.19 as of fiscal year 2025, which is generally considered healthy.

What is STANDARD BIOTOOLS INC's debt-to-equity ratio?

STANDARD BIOTOOLS INC (LAB) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is STANDARD BIOTOOLS INC's return on assets (ROA)?

STANDARD BIOTOOLS INC (LAB) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is STANDARD BIOTOOLS INC's cash runway?

Based on fiscal year 2025 data, STANDARD BIOTOOLS INC (LAB) had $120.9M in cash against an annual operating cash burn of $74.3M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is STANDARD BIOTOOLS INC's Altman Z-Score?

STANDARD BIOTOOLS INC (LAB) has an Altman Z-Score of -1.33, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is STANDARD BIOTOOLS INC's Piotroski F-Score?

STANDARD BIOTOOLS INC (LAB) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are STANDARD BIOTOOLS INC's earnings high quality?

STANDARD BIOTOOLS INC (LAB) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can STANDARD BIOTOOLS INC cover its interest payments?

STANDARD BIOTOOLS INC (LAB) has an interest coverage ratio of -4240.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is STANDARD BIOTOOLS INC?

STANDARD BIOTOOLS INC (LAB) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.